ArticleAnais brasileiros de dermatologia

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria.

Fikriye Kalkan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.